Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…
WuXi Biologics Secures MSCI AAA ESG Rating for Third Consecutive Year, Reinforcing Global Sustainability Leadership WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced that it has achieved the highly esteemed AAA ESG rating…
AstraZeneca Expands U.S. Manufacturing Footprint with $4.5 Billion Virginia Facility, Creating 3,600 Jobs and Advancing Domestic Biopharmaceutical Production AstraZeneca has announced an expanded commitment to U.S. manufacturing with a $4.5 billion investment in a new state-of-the-art production facility in Virginia,…
bioAffinity Technologies Reports Record Third-Quarter 2025 Growth in CyPath® Lung Test Adoption, Driven by Expanding Clinical Use and Physician Confidence bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company pioneering noninvasive diagnostics for lung cancer and other lung diseases, has…
TCGX Closes Oversubscribed $1.3 Billion Fund III, Strengthening Its Position in Global Biopharma Investment TCG Crossover (“TCGX”), a leading global investment firm focused on the biotechnology and life sciences sector, announced the successful close of its third fund—TCGX Fund III—with…
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…
GSK Commits $30B To Boost US R&D, Manufacturing Operations The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or completely canceling previous commitments.GSK will pump $30 billion into the U.S. over…
Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector When Akeso was starting out some 13 years ago, the leadership team had $3 million and a bold goal to move China’s drug industry toward innovation. When Akeso…
Pioneering sustainable transatlantic transport to cut emissions in pharmaceutical supply chains Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using…
Sanofi Joins Growing Group of Pharmas Pulling Back From UK Merck, Eli Lilly and AstraZeneca have similarly suspended or outright canceled investments in the U.K. in the past week after a sizeable increase in a mandatory levy in the region…
Royalty Pharma and Deloitte Release Landmark Study on the Role of Royalties in Funding Biopharma Innovation Royalty Pharma plc (Nasdaq: RPRX), the world’s largest acquirer of biopharmaceutical royalties and a key investor in life sciences innovation, has announced the publication…
Alnylam Pharmaceuticals Prices Upsized $575 Million Convertible Senior Notes Offering, Strengthening Balance Sheet and Advancing Growth Strategy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized global leader in RNA interference (RNAi) therapeutics, has announced the successful pricing of its private offering…